Last reviewed · How we verify
Caralluma Fimbriata
Caralluma fimbriata is thought to suppress appetite and reduce food intake by inhibiting the activity of citrate lyase, an enzyme involved in fat synthesis.
Caralluma fimbriata is thought to suppress appetite and reduce food intake by inhibiting the activity of citrate lyase, an enzyme involved in fat synthesis. Used for Weight loss.
At a glance
| Generic name | Caralluma Fimbriata |
|---|---|
| Also known as | C.fimbriata |
| Sponsor | RDC Clinical Pty Ltd |
| Target | citrate lyase |
| Modality | Small molecule |
| Therapeutic area | Obesity |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of caralluma fimbriata is not fully understood, but it is believed to work by suppressing appetite and reducing food intake. This is thought to be achieved through the inhibition of citrate lyase, an enzyme involved in fat synthesis. As a result, caralluma fimbriata may help with weight loss and improve overall metabolic health.
Approved indications
- Weight loss
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Caralluma Fimbriata CI brief — competitive landscape report
- Caralluma Fimbriata updates RSS · CI watch RSS
- RDC Clinical Pty Ltd portfolio CI